Spark Therapeutics Inc (ONCE) was Initiated by Stifel to “Buy” and the brokerage firm has set the Price Target at $73. Stifel advised their investors in a research report released on Sep 2, 2016.
Many Wall Street Analysts have commented on Spark Therapeutics Inc. RBC Capital Mkts Initiated Spark Therapeutics Inc on Jul 12, 2016 to “Outperform”, Price Target of the shares are set at $70.Shares were Reiterated by Cantor Fitzgerald on Jun 23, 2016 to “Buy” and Lowered the Price Target to $ 94 from a previous price target of $100 .Company shares were Reiterated by SunTrust on Jun 21, 2016 to “Buy”, Firm has raised the Price Target to $ 72 from a previous price target of $64 .
On the company’s financial health, Spark Therapeutics Inc reported $-1.04 EPS for the quarter, missing the analyst consensus estimate by $ -0.05 based on the information available during the earnings call on Aug 10, 2016. Analyst had a consensus of $-0.99. The company had revenue of $1.29 million for the quarter, compared to analysts expectations of $1.30 million. During the same quarter in the previous year, the company posted $-0.60 EPS.
Spark Therapeutics Inc opened for trading at $56.53 and hit $57.69 on the upside on Thursday, eventually ending the session at $57.55, with a gain of 1.71% or 0.97 points. The heightened volatility saw the trading volume jump to 3,20,827 shares. Company has a market cap of $1,762 M.
In a different news, on Aug 17, 2016, Katherine A High (director officer ) sold 10,000 shares at $63.30 per share price. According to the SEC, on Aug 17, 2016, Jeffrey D Marrazzo (Chief Executive Officer) sold 10,000 shares at $63.32 per share price. On Aug 12, 2016, Anand Mehra (director) sold 29,963 shares at $60.55 per share price, according to the Form-4 filing with the securities and exchange commission.
Spark Therapeutics Inc. (Spark) is engaged in developing products in the field of gene therapy. Spark’s product candidate SPK-RPE65 which is in Phase III clinical trial stage targets a group of rare blinding conditions known as inherited retinal dystrophies (IRDs) caused by non-sex linked or autosomal recessive mutations in the RPE65 gene. Spark is also developing various follow-on product candidates targeting other IRDs including SPK-CHM for the treatment of choroideremia (CHM). SPK-CHM is in Phase I/II dose-escalating clinical trial stage. The Company’s product development portfolio includes product candidates targeting expression of genes in the liver with a focus on hematologic disorders. The Company is also engaged in the development and commercialization of product candidates in its SPK-FIX program for the treatment of hemophilia B. Spark also has preclinical programs in development for the treatment of hemophilia A and neurodegenerative diseases.